ZTS Stock Recent News

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 13, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/eve.

The SPDR S&P 500 ETF was up 9.13% in November, Vanguard's Dividend Appreciation ETF was up 7.47%, my watchlist beat both with a return of 10.24%. The top 15 dividend growth stocks for December offer an average dividend yield of 1.99% and appear to be about 34% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is rocking a cool 11.76% annualized return, beating VIG by 2.36% and SPY by 1.52%.

While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Kristin Peck, Zoetis CEO, joins 'Squawk on the Street' to discuss her insights into livestock and pet care products, how tied Zoetis' business is to the macro economy, and more.

Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors?

Zoetis is an animal health company specializing in the development and manufacturing of veterinary pharmaceuticals and vaccines for both livestock and companion animals. For FY2023, the company has announced a $1 billion investment to enhance manufacturing capacity for monoclonal antibodies. This is the largest investment in its history. The company is sacrificing the short term to benefit in the long term. Which seems like a great decision and demonstrates an amazing corporate culture.

Investors looking for stocks in the Medical - Drugs sector might want to consider either Jazz Pharmaceuticals (JAZZ) or Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zoetis Inc., the world's largest provider of animal medicines, vaccines, and diagnostic products, is capitalizing on the growing trend of pet pampering. The company dominates the companion animal and cattle markets, which are anti-cyclical and have strong growth potential. Zoetis expects to sustain above-average growth through innovation, strategic investments, and leveraging its broad product portfolio.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, Sept. 12, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:55 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-pr.